STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules
Rhea-AI Summary
STRATA Skin Sciences (NASDAQ: SSKN), a medical technology company focused on dermatologic treatments, has announced a $2.42 million registered direct offering of common stock. The company will sell 1,097,547 shares at $2.204 per share, priced at-market under Nasdaq rules.
The offering, expected to close around September 4, 2025, is being conducted with institutional investors, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent. STRATA plans to use the proceeds for working capital and general corporate purposes. The offering is being made through a shelf registration statement previously declared effective by the SEC.
Positive
- Secured immediate funding of $2.42 million for working capital
- Successfully arranged institutional investment at market price
- Offering conducted through existing shelf registration, streamlining the process
Negative
- Potential dilution for existing shareholders
- Relatively small offering size may indicate limited investor interest
News Market Reaction
On the day this news was published, SSKN declined 33.57%, reflecting a significant negative market reaction. Argus tracked a trough of -39.7% from its starting point during tracking. Our momentum scanner triggered 30 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $12M at that time.
Data tracked by StockTitan Argus on the day of publication.
HORSHAM, Pa., Sept. 03, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has entered into definitive securities purchase agreements with certain institutional investors for the purchase and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of
Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering.
The closing of the registered direct offering is expected to occur on or about September 4, 2025, subject to the satisfaction of customary closing conditions.
The gross proceeds to The Company from the registered direct offering, before deducting the placement agent fees and other offering expenses payable by the Company, are expected to be approximately
The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-283418), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on December 18, 2024. The registered direct offering is being made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement, that will be filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice. For more information, please visit www.strataskinsciences.com.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. These statements, the Company’s ability to launch and sell products recently acquired or to be developed in the future, the Company’s ability to develop social media marketing campaigns, direct to consumer marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry and our customers and patients in general, as well as more specific risks and uncertainties set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.
Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com
FAQ
What is the size and price of STRATA Skin Sciences (SSKN) September 2025 offering?
How will STRATA Skin Sciences use the proceeds from the $2.42M offering?
Who is the placement agent for SSKN's September 2025 stock offering?
When will STRATA Skin Sciences' registered direct offering close?
What type of investors are participating in SSKN's $2.42M offering?
